Philip W. Kantoff

Philip W. Kantoff is a medical oncologist. He is the chairman and chief executive officer (CEO) of Convergent Therapeutics. He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021. He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.

Education

Kantoff grew up in Forest Hills, New York City. He attended Brown University, where he earned his undergraduate and medical degrees through the Program in Liberal Medical Education. After 28 years at Dana-Farber, Kantoff joined Memorial Sloan Kettering Cancer Center in 2015 to replace George J. Bosl as the Chairman of Medicine. He serves as a Professor of Medicine at the Weill Cornell Medical College. He was also awarded an NCI SPORE grant for prostate cancer from 2001 to 2015 and a NCI Program Project Grant in 2019 on DNA Damage Repair Alterations in Prostate Cancer. In 2018, Kantoff became an independent director at Context Therapeutics.

In 2021, Kantoff was appointed chairman and chief executive officer of Convergent Therapeutics, a pharmaceutical company based in Cambridge, Massachusetts that focuses on radiopharmaceutical cancer therapies.

Significant publications

Awards Inaugural Nancy and Jerome Kohlberg Chair in Medicine, Harvard Medical School Giants in Cancer Care Elected member, Association of American Physicians, 2018